BACKGROUND Homozygous familial hypercholesterolemia is characterized by premature cardiovascular disease caused by markedly elevated levels of low-density lipoprotein (LDL) cholesterol. This disorder is associated with genetic variants that result in virtually absent (null–null) or impaired (non-null) LDL-receptor activity. Loss-offunction variants in the gene encoding angiopoietin-like 3 (ANGPTL3) are associated with hypolipidemia and protection against atherosclerotic cardiovascular disease. Evinacumab, a monoclonal antibody against ANGPTL3, has shown potential benefit in patients with homozygous familial hypercholesterolemia. METHODS In this double-blind, placebo-controlled, phase 3 trial, we randomly assigned in a 2:1 ratio 65 patients with homozygous familial hypercholesterolemia who were receiving stable lipid-lowering therapy to receive an intravenous infusion of evinacumab (at a dose of 15 mg per kilogram of body weight) every 4 weeks or placebo. The primary outcome was the percent change from baseline in the LDL cholesterol level at week 24. RESULTS The mean baseline LDL cholesterol level in the two groups was 255.1 mg per deciliter, despite the receipt of maximum doses of background lipid-lowering therapy. At week 24, patients in the evinacumab group had a relative reduction from baseline in the LDL cholesterol level of 47.1%, as compared with an increase of 1.9% in the placebo group, for a between-group least-squares mean difference of –49.0 percentage points (95% confidence interval [CI], –65.0 to –33.1; P 0.001); the between-group least-squares mean absolute difference in the LDL cholesterol level was –132.1 mg per deciliter (95% CI, –175.3 to –88.9; P 0.001). The LDL cholesterol level was lower in the evinacumab group than in the placebo group in patients with null–null variants (–43.4% vs. +16.2%) and in those with non-null variants (–49.1% vs. –3.8%). Adverse events were similar in the two groups. CONCLUSIONS In patients with homozygous familial hypercholesterolemia receiving maximum doses of lipid-lowering therapy, the reduction from baseline in the LDL cholesterol level in the evinacumab group, as compared with the small increase in the placebo group, resulted in a between-group difference of 49.0 percentage points at 24 weeks. (Funded by Regeneron Pharmaceuticals; ELIPSE HoFH ClinicalTrials.gov number, NCT03399786.)

Evinacumab for Homozygous Familial Hypercholesterolemia / Gerald Watts, .; Deeba, Farrah; Sullivan, David; Donald Bonnitcha, Paul; San Min, San; Jacintha Nanayakkara, Nimalie; Ebenbichler, Christopher; Tschoner, Alexander; Engler, Clemens; Gaudet, Daniel; Roy, Nathalie; Blackburn, David; Bergeron, Jean; Villeneuve, Hisee; Saheb, Samir; Gallo, Antonio; Beliard, Sophia; Dussol, Bertrand; Morange, Sophie; Poullin, Pascale; Valero, Rene; Milionis, Charalampos; Filippas-Ntekouan, Sebastian; Klouras, Eleftherios; Kolovou, Genovefa; Hatzigeorgiou, George; Rammos, Spyridon; Rubba, PAOLO OSVALDO FEDERICO; Iannuzzo, Gabriella; Harada-Shiba, Mariko; Son, Cheol; Makino, Hisashi; Hosoda, Kiminori; Matsuki, Kota; Kohmo, Kyoko; Matsubara, Masaki; Ogura, Masatsune; Noguchio, Michio; Matsuo, Miki; Koezuka, Ryo; Tamanaha, Tamiko; Tomita, Tsutomu; Ohata, Yoko; Otsubo, Yoshihiko; Koyanagi, Noriaki; Kawashiri, Masaaki; Tada, Hayato; Nohara, Atsushi; Nomura, Akihiro; Okada, Hirofumi; Fujii, Naohiko; Hayashi, Daisuke; Yonemoto, Sayoko; Fukuda, Shungo; Yanagi, Koji; Ryo, Miwa; Koseki, Masahiro; Nishida, Makoto; Okada, Takeshi; Stroes, Erik; Reeskamp, Laurens; Stols-Goncalves, Daniela; Hamulyak, Eva; H Liem, Anho; M Akkerhuis, Jurgen; R Nierop, Pieter; M van Dalen, Bastiaan; E van de Poll, Sweder W; M van Miltenburg-van Zijl, Adriana J; J Veerhoek, Marinus; Raal, Frederick; Amrat Bhana, Sindeep; Mitchenko, Olena; Romanov, Vadym; Chulaevska, Iryna; Rudenko, Leonid; Beregova, Olena; Vakaliuk, Igor; Drapchak, Iryna; Tymochko, Natalia; Isayeva, Anna; Buriakovska, Olena; Vovchenko, Maryna; Tseluyko, Vira; Matviychuk, Nataliya; Yakovleva, Larysa; Duell, Paul; Barton Purnell, Jonathan; Rosenson, Robert; Smith, Donald; Halloran, Theresa; Gottlieb, Robert; A McCullough, Peter; P Rosol, Zachary; Y Lee, Andy; M Barbin, Clay; J Baum, Seth; Mendelson, Reina; Wright, Melissa; Hemphill, Linda; Fahed, Akl; Turner, Traci; Ellard, Angela. - In: THE NEW ENGLAND JOURNAL OF MEDICINE. - ISSN 0028-4793. - 383:8(2020), pp. 711-720. [10.1056/NEJMoa2004215]

Evinacumab for Homozygous Familial Hypercholesterolemia

Antonio Gallo;Paolo Rubba;Gabriella Iannuzzo;
2020

Abstract

BACKGROUND Homozygous familial hypercholesterolemia is characterized by premature cardiovascular disease caused by markedly elevated levels of low-density lipoprotein (LDL) cholesterol. This disorder is associated with genetic variants that result in virtually absent (null–null) or impaired (non-null) LDL-receptor activity. Loss-offunction variants in the gene encoding angiopoietin-like 3 (ANGPTL3) are associated with hypolipidemia and protection against atherosclerotic cardiovascular disease. Evinacumab, a monoclonal antibody against ANGPTL3, has shown potential benefit in patients with homozygous familial hypercholesterolemia. METHODS In this double-blind, placebo-controlled, phase 3 trial, we randomly assigned in a 2:1 ratio 65 patients with homozygous familial hypercholesterolemia who were receiving stable lipid-lowering therapy to receive an intravenous infusion of evinacumab (at a dose of 15 mg per kilogram of body weight) every 4 weeks or placebo. The primary outcome was the percent change from baseline in the LDL cholesterol level at week 24. RESULTS The mean baseline LDL cholesterol level in the two groups was 255.1 mg per deciliter, despite the receipt of maximum doses of background lipid-lowering therapy. At week 24, patients in the evinacumab group had a relative reduction from baseline in the LDL cholesterol level of 47.1%, as compared with an increase of 1.9% in the placebo group, for a between-group least-squares mean difference of –49.0 percentage points (95% confidence interval [CI], –65.0 to –33.1; P 0.001); the between-group least-squares mean absolute difference in the LDL cholesterol level was –132.1 mg per deciliter (95% CI, –175.3 to –88.9; P 0.001). The LDL cholesterol level was lower in the evinacumab group than in the placebo group in patients with null–null variants (–43.4% vs. +16.2%) and in those with non-null variants (–49.1% vs. –3.8%). Adverse events were similar in the two groups. CONCLUSIONS In patients with homozygous familial hypercholesterolemia receiving maximum doses of lipid-lowering therapy, the reduction from baseline in the LDL cholesterol level in the evinacumab group, as compared with the small increase in the placebo group, resulted in a between-group difference of 49.0 percentage points at 24 weeks. (Funded by Regeneron Pharmaceuticals; ELIPSE HoFH ClinicalTrials.gov number, NCT03399786.)
2020
Evinacumab for Homozygous Familial Hypercholesterolemia / Gerald Watts, .; Deeba, Farrah; Sullivan, David; Donald Bonnitcha, Paul; San Min, San; Jacintha Nanayakkara, Nimalie; Ebenbichler, Christopher; Tschoner, Alexander; Engler, Clemens; Gaudet, Daniel; Roy, Nathalie; Blackburn, David; Bergeron, Jean; Villeneuve, Hisee; Saheb, Samir; Gallo, Antonio; Beliard, Sophia; Dussol, Bertrand; Morange, Sophie; Poullin, Pascale; Valero, Rene; Milionis, Charalampos; Filippas-Ntekouan, Sebastian; Klouras, Eleftherios; Kolovou, Genovefa; Hatzigeorgiou, George; Rammos, Spyridon; Rubba, PAOLO OSVALDO FEDERICO; Iannuzzo, Gabriella; Harada-Shiba, Mariko; Son, Cheol; Makino, Hisashi; Hosoda, Kiminori; Matsuki, Kota; Kohmo, Kyoko; Matsubara, Masaki; Ogura, Masatsune; Noguchio, Michio; Matsuo, Miki; Koezuka, Ryo; Tamanaha, Tamiko; Tomita, Tsutomu; Ohata, Yoko; Otsubo, Yoshihiko; Koyanagi, Noriaki; Kawashiri, Masaaki; Tada, Hayato; Nohara, Atsushi; Nomura, Akihiro; Okada, Hirofumi; Fujii, Naohiko; Hayashi, Daisuke; Yonemoto, Sayoko; Fukuda, Shungo; Yanagi, Koji; Ryo, Miwa; Koseki, Masahiro; Nishida, Makoto; Okada, Takeshi; Stroes, Erik; Reeskamp, Laurens; Stols-Goncalves, Daniela; Hamulyak, Eva; H Liem, Anho; M Akkerhuis, Jurgen; R Nierop, Pieter; M van Dalen, Bastiaan; E van de Poll, Sweder W; M van Miltenburg-van Zijl, Adriana J; J Veerhoek, Marinus; Raal, Frederick; Amrat Bhana, Sindeep; Mitchenko, Olena; Romanov, Vadym; Chulaevska, Iryna; Rudenko, Leonid; Beregova, Olena; Vakaliuk, Igor; Drapchak, Iryna; Tymochko, Natalia; Isayeva, Anna; Buriakovska, Olena; Vovchenko, Maryna; Tseluyko, Vira; Matviychuk, Nataliya; Yakovleva, Larysa; Duell, Paul; Barton Purnell, Jonathan; Rosenson, Robert; Smith, Donald; Halloran, Theresa; Gottlieb, Robert; A McCullough, Peter; P Rosol, Zachary; Y Lee, Andy; M Barbin, Clay; J Baum, Seth; Mendelson, Reina; Wright, Melissa; Hemphill, Linda; Fahed, Akl; Turner, Traci; Ellard, Angela. - In: THE NEW ENGLAND JOURNAL OF MEDICINE. - ISSN 0028-4793. - 383:8(2020), pp. 711-720. [10.1056/NEJMoa2004215]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/820780
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 386
  • ???jsp.display-item.citation.isi??? 344
social impact